Welcome to our dedicated page for Bio Green Med Solution SEC filings (Ticker: BGMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Bio Green Med Solution, Inc. (BGMS) brings together the company’s official reports to the U.S. Securities and Exchange Commission, including Form 8-K current reports and other key documents. These filings describe how the company has transitioned from its former identity as Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, to a diversified business focused primarily on fire safety protection and distribution activities anchored by its acquisition of FITTERS Sdn. Bhd. in Malaysia.
Through its 8-K filings, Bio Green Med Solution, Inc. discloses material events such as the completion of the FITTERS Sdn. Bhd. share exchange transaction, the Asset Purchase Agreement with Tethra Biosciences Inc. for the sale of patent rights related to plogosertib, and the liquidation of its UK subsidiary, Cyclacel Limited. These documents also cover capital markets actions, including a one-for-fifteen reverse stock split of its common stock, Warrant Exchange Agreements that exchanged existing warrants for new common shares, and a Nasdaq notice regarding the minimum Market Value of Publicly Held Shares requirement for its 6% Convertible Exchangeable Preferred Stock (BGMSP).
Filings further address governance and compensation matters, such as the resignation and appointment of independent directors, committee assignments for the Audit, Compensation and Organization, and Nominating and Governance Committees, and confirmation of director independence and financial literacy under SEC and Nasdaq standards. Dividend declarations on the company’s 6% Convertible Exchangeable Preferred Stock are also documented in Form 8-K reports.
On this page, users can access Bio Green Med Solution, Inc.’s SEC filings as they are made available from EDGAR and review AI-generated summaries that explain the main points of lengthy documents, including 10-K annual reports, 10-Q quarterly reports, and Form 4 insider transaction reports where applicable. These tools help readers quickly understand complex regulatory disclosures, track changes in the company’s business focus, and follow developments affecting its common and preferred equity securities.
Bio Green Med Solution (BGMS) reported an insider transaction on a Form 4. A reporting person identified by signature as Kua Khai Loon, noted as a Director, sold 242,477 shares of Common Stock on 10/30/2025 at a price of $1.8 per share (transaction code S). Following the sale, the filing states the reporting person beneficially owned 0 shares, with ownership listed as Direct. The form indicates it was filed by one reporting person.
Bio Green Med Solution (BGMS) disclosed an insider transaction on a Form 4. On October 30, 2025, a 10% owner sold 248,814 shares of common stock (Transaction Code S) at $1.8 per share. After the sale, the reporting person held 0 shares directly.
Bio Green Med Solution (BGMS) insider transaction: A reporting person filed a Form 4 showing a sale of common stock. On 10/29/2025, the insider sold 110,749 shares of BGMS common stock at a price of $1.834 per share. Following the transaction, the filer beneficially owned 140,760 shares, held as Direct (D) ownership.
The filing indicates it was submitted by one reporting person and relates to non-derivative securities only; no derivative transactions were reported. The issuer is Bio Green Med Solution, Inc. (BGMS).
Bio Green Med Solution (BGMS) insider activity: Yap Kim Choy, a director and 10% owner, reported a sale of 13,111 shares of common stock on 10/28/2025 at $1.828 per share (transaction code S). Following the transaction, he beneficially owned 251,509 shares, held directly. This update was disclosed on Form 4.
Bio Green Med Solution (BGMS) insider filing reports that director and 10% owner Yap Kim Choy sold 120,250 shares of common stock at $2.118 on 10/27/2025.
Following the sale, the filing shows 264,620 shares beneficially owned with direct ownership.
Bio Green Med Solution (BGMS) reported a Form 4 insider transaction showing a sale of 19,858 shares of common stock at $1.99 on October 24, 2025 (transaction code S).
Following the sale, the reporting person beneficially owned 248,814 shares, held directly.
Bio Green Med Solution (BGMS) insider Yap Kim Choy reported a sale of common stock on 10/24/2025 under transaction code S (sale). The filing shows 19,595 shares disposed at a price of $1.902 per share.
After this transaction, the reporting person beneficially owns 384,870 shares, held directly. The filer is listed as a 10% owner.
Bio Green Med Solution (BGMS) reported insider activity on Form 4. Director Datuk Tan Chor How Christopher sold 92,352 shares of common stock on 10/21/2025 at a price of $3.005 per share (transaction code S). Following this sale, the reporting person beneficially owns 279,248 shares, held directly. This filing discloses a change in insider holdings and reflects a single reported transaction.
Bio Green Med Solution (BGMS) reported an insider transaction on Form 4. On 10/20/2025, 10% owner Datuk Tan Chor How Christopher sold 108,107 shares of common stock at $3.088 per share (Transaction Code: S). Following the sale, the reporting person beneficially owns 371,600 shares, held directly.
Bio Green Med Solution (BGMS) insider activity: Reporting person Kua Khai Loon, a director, filed a Form 4 disclosing open-market sales of BGMS common stock. On 10/15/2025, 7,479 shares were sold at $5.661, leaving 330,681 shares beneficially owned. On 10/16/2025, 88,204 shares were sold at $4.217, leaving 242,477 shares beneficially owned. Ownership is listed as Direct. The filing was made by one reporting person.
FAQ
What is the current stock price of Bio Green Med Solution (BGMS)?
What is the market cap of Bio Green Med Solution (BGMS)?
